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Summary Effects of amphotericin B on production of endogenous tumour necrosis factor alpha (TNF-a) and anti-tumour activity in mice was
examined. Intravenous administration of Fungizone, an amphotericin B preparation complexed with deoxycholate, augmented the induction
of endogenous TNF in response to a second stimulus with intravenous doses of FK23 (heat-killed Enterococcus faecalis). This augmentation
was observed when more than 1.8 9g of Fungizone was injected intravenously before intravenous dosing of FK23. The time interval between
priming injection of Fungizone and secondary injection of FK23 for the maximal effect was 3 h. Similar augmentation of TNF production was
also observed in amphotericin B-primed and FK23-injected mice. Correspondingly, anti-tumour activity of the combined, intravenous injection
of Fungizone and FK23 with a 3-h interval was examined. Growth of Meth A fibrosarcoma was clearly inhibited by this combination but not by
administration of either one alone. These results suggest that amphotericin B is able to elicit anti-tumour activity, perhaps through activation
of the immune system, and in particular augmentation of the induction of endogenous TNF.
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Fungizone, a deoxycholate-complexed formulation of ampho-
tericin B, is in broad use for the treatment of deep mycoses.
Amphotericin B is known to activate macrophage functions, in
terms of oxidative burst (Wolf and Massoff, 1990), fungicidal
activity (Perfect et al, 1987) and production of a cytokine, tumour
necrosis factor alpha (TNF-a), in vitro (Gelfand et al, 1988; Chia
and Pollack, 1989; Chia and McManus, 1990). TNF is a key
cytokine, which regulates host defence mechanisms against
tumour cells as well as pathogenic microbes (Old, 1987). Efficient
induction of TNF reportedly requires two steps of macrophage
stimulation - a priming step and a triggering step (Mizuno, 1992).
We recently demonstrated the priming activity of amphotericin B
to induce in vitro and in vivo TNF production in mice (Tokuda et
al, 1993; Yamaguchi et al, 1993). This suggests that amphotericin
B may elicit some anti-tumour activity in vivo when used in
combination with an appropriate triggering agent for TNF produc-
tion. It is clinically important to check this possibility because
amphotericin B preparations, especially Fungizone, are often
prescribed for immunocompromised cancer patients with deep-
seated mycoses. We chose FK23, a heat-killed cell preparation of
Enterococcusfaecalis, as a TNF trigger for this study (Abe et al,
1993) and here report that treatment ofmice with acombination of
Fungizone and FK23 induced significant TNF production and
inhibited tumour growth.
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MATERIALS AND METHODS
Animals and tumours
Male BALB/c mice were purchased from Japan SLC (Shizuoka,
Japan) and used at 8 weeks of age. Meth A fibrosarcoma was main-
tained in the peritoneal cavity of these mice by weekly passage.
Experiments were performed according to the guidelines for the
care and use ofanimals approved by Teikyo University.
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Figure 1 Dose-response curve of Fungizone in priming for TNF production.
Fungizone or saline (0 9g per mouse) was administered intravenously into
BALB/c mice, and 3 h later FK23 (300 igg per mouse) was also injected
intravenously. Mice were exsanguinated 2 h later to collect the peripheral
blood. TNF activity in serum was measured by an in vitro cytotoxic assay of
L-929 cells as described in 'Materials and methods'. Each datum point and
vertical bar represent the mean value of six samples and their standard
deviation respectively. *,** Significant difference from each corresponding
group not treated with Fungizone (*P < 0.05; **P < 0.01)
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Chemical reagents
FK23 (heat-killed Enterococcus faecalis) was generously
provided by Nichinichi Pharmaceutical (Mie, Japan). Fungizone
and amphotericin B were purchased from Bristol-Meyers Squibb
Japan (Tokyo, Japan) and Sigma Chemical (MO, USA). Sodium
deoxycholate was obtained from Difco (MI, USA).
TNF assay
Fungizone or amphotericin B was administered intravenously to
mice, followed 3 h laterby intravenous injection ofFK23 at adose
of 300 gg per mouse, which was optimal to induce TNF in mice.
Two hours later the mice were exsanguinated and their serum was
obtained. TNF activity of serum was assayed with L-929 mouse
fibroblasts in the presence of actinomycin D (1 gg ml-') by the
method of Ruff and Gifford (1980) with minor modifications
(Okutomi et al, 1987). Units ofTNFactivity were calculated as the
dilution factor of serum allowing survival of half of the L-929
cells with rTNF-a (PAC4D, 2 x 106 u ml-1; donated by Asahi
Chemical, Tokyo, Japan) as an internal reference in each assay to
avoid possible fluctuations because ofculture conditions.
Anti-tumour therapeutic effect
Meth A (2 x 10 cells) tumour cells were inoculated intradermally
into the abdomens of 8-week-old BALB/c mice. Tumours devel-
oped within a few days after inoculation and reached 4.5-5 mm in
diameter on day 5. The mice were then intravenously administered
Fungizone and 3 h thereafter FK23 (300 jig per mouse) was
injected intravenously. Tumour diameter was measured using a
vernier calliper. Six mice were used for each group.
Statistical analysis
Statistical analysis for difference among groups was examined
using Student's t-test.
RESULTS
Effects of amphotericin B on production of
endogenous TNF
We previously reported that FK23 had a triggering activity to
induce endogenous TNF production (Abe et al, 1993). Here, we
first examined the effect of amphotericin B on production of
endogenous TNF in response to triggering by FK23. Fungizone,
an amphotericin B preparation complexed with deoxycholate, was
injected intravenously to mice, and 3 h later FK23 was also
injected intravenously. Two hours later blood specimens were
taken from each mouse to estimate TNF activity. Figure 1 shows
that intravenous administration of more than 1.8 jig ofFungizone
enhanced the production ofendogenous TNF in a dose-dependent
manner and that 55 jig of Fungizone induced about 300 u ml-1 of
TNF provided that FK23 was subsequently administered. As the
time interval between priming and triggering has been reported to
influence critically the level of endogenous production of TNF
(Okutomi and Yamazaki, 1988), we examined TNF production
using various intervals between sequential injections of the two
preparations. As shown in Figure 2, the maximum augmentation
of TNF production was observed when FK23 was injected 3 h
after injection of Fungizone, and the production gradually
decreased with lengthening ofthe interval up to 18 h.
The Fungizone preparation contains not only amphotericin B
but also sodium deoxycholate. To checkthatit was amphotericin B
that augmented the induction of endogenous TNF, we examined
the effect of these components on the induction. As shown in
Figure 3, intravenous administration of 30 jig of amphotericin B
dissolved in 0.25% dimethyl sulphoxide (DMSO) augmented the
induction to a level almostequal with that achievedby intravenous
administration of 55 jg of Fungizone, which consisted 30 jig of
amphotericin B and 25 jg of sodium deoxycholate. Intravenous
administration of25 jg ofsodium deoxycholate or 0.25% DMSO,
however, did not cause this augmentation.
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Figure 2 Time course of priming effect of Fungizone. Fungizone (55 9g per
mouse) was administered intravenously, and 0-18 h later FK23 (300 igg per
mouse) was also injected intravenously. Two hours later mice were
exsanguinated to collect the peripheral blood, and TNF activity in serum was
measured. Each datum point and vertical bar represent the mean value of six
samples and their standard deviation respectively. **P< 0.01. For detail, see
footnotes to Figure 1
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Figure 3 Priming effects of Fungizone and amphotericin B. Fungizone
[55 9g per mouse; a complex of amphotericin B (30 9g) and sodium
deoxycholate, DOC (25 9g)], amphotericin B (30 gg per mouse; dissolved in
0.25% DMSO), DOC (25 gg per mouse) or DMSO (0.25% DMSO) was
administered intravenously, and 3 h later FK23 (300jg per mouse) was
injected intravenously. After 2 h, mice were exsanguinated to prepare serum
specimens, and TNF activity in serum was measured. **P< 0.01. For detail,
see footnotes to Figure 1
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Figure 4 Anti-tumour activity of combination therapy of Fungizone and FK23.
Meth A cells (2 x 105cells) were inoculated intradermally into the abdomens
of BALB/c mice on day 0. The mice were intravenously administered 55 9g
per mouse of Fungizone (0, O), saline (A, A) (A) or 251lg per mouse of
DOC (A, A) (B). Three hours later, 300 9g per mouse FK23 (0, A) or saline
(O, A) was injected intravenously on day indicated by arrows. *,**
Statistically significant difference from the other groups (*P< 0.05;
**P< 0.01)
Combination therapy of amphotericin B and FK23
against Meth A fibrosarcoma
Based on the abovefindings, we examined the therapeutic activity
Of the combination of Fungizone and FK23 against Meth A
fibrosarcoma in mice. From S days after the tumour inoculation,
the mice received sequential administration of 55 gg Fungizone
and 300 ,ug of FK23 at 3-h intervals. This treatment was repeated
fourtimes for4 consecutive days or for 14 days at3-day intervals.
As shown in Figure 4A and B, the growth of tumours in mice
treated with Fungizone plus FK23 was slower than that in the
animals treated with either preparation alone. Combination
therapy with Fungizone plus FK23 administered under the
schedule with 3-day intervals, in particular, clearly inhibited
20orgot nil2 asatrtuoriouain
DISCUSSION
We have demonstrated the significant priming activity of
Fungizone on FK23-induced TNF production in mice and the
anti-tumour activity ofcombined administration ofFungizone and
FK23. Priming activity of Fungizone for TNF production seems
reasonable because amphotericin B is found to have a priming
activity for TNF production when a triggering agent, OK432 (a
streptococcal preparation), is subsequently administered (Tokuda
et al, 1993; Yamaguchi et al, 1993). Clinical dosage ofFungizone
for maintenance therapy of patients with severe mycoses, such
as invasive pulmonary aspergillosis, is recommended to be 1.0-
1.5 mg kg-' day-' as titre ofamphotericin B, which corresponds to
about 25-38 ,ug permouse perday. Therefore, an effective dose of
Fungizone (55 ,ug per mouse, which contains 30 ,ug of ampho-
tericin B) means that aclinical dose ofFungizone may prime TNF
production in vivo.
The most important finding in this work is that a combination of
amphotericin B and FK23 inhibited the growth of Meth A fibro-
sarcoma. FK23 was reported to inhibit the growth of highly anti-
genic tumours but not Meth A fibrosarcoma (Abe et al, 1993). We
have confmned that neither FK23 nor amphotericin B has any
significant anti-tumour activity in this Meth A model. The growth
ofMeth A fibrosarcoma is reported tobe clearly inhibited by some
other drug combinations with TNF-inducing activity, for example
muramyl dipeptide plus OK432 (Okutomi et al, 1990). Therefore,
the anti-tumour activity ofthe combination ofamphotericin B and
FK23 may be elicited by efficient production of TNF. This possi-
bility is also supported by the finding that adosing schedule ofthe
combination at 3-day intervals was more effective than that of
consecutive day dosing, perhaps because the former schedule
allowed effectiveproduction ofTNFforalongerperiodin tumour-
bearing mice (Mizuno, 1992). In this context, sufficient endoge-
nous production ofTNF was reported to inhibit growth ofnot only
a chemically induced tumour but also spontaneously induced
tumours (Okutomi et al, 1990). Moreover, growth of Meth A
tumour was inhibited by TNF in vitro and Gatanaga et al (1989)
reported that growth of Meth A inoculated intradermally to mice
was inhibited by intravenous administration ofTNF. In either case,
theroleofTNFinthis anti-tumouraction ofamphotericinB should
be checked by aneutralization experiment with anti-TNF antibody.
Amphotericin B is an antifungal drug useful forthe treatment of
severe deep mycoses. Cancer patients, particularly leukaemia
patients, are at high risk of developing invasive fungal infections.
In these patients, amphotericin B may have dualtherapeutic effects
when combined with some TNF-triggering agents, i.e. antifungal
and anti-tumour agents. The finding from a clinical study reported
by Sculier and Body (1991) that the rate of objective response to
anti-tumour chemotherapy in patients with lung cancer increased
when amphotericin B was injected by intravenous infusion before
cancer chemotherapy treatment would also suggest a beneficial
effect of amphotericin B. However, clinical trials to develop this
combination therapy with amphotericin B require toxicological
investigation ofthe combination therapy in cancer patients.
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